To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have DSCRT or another peritoneal solid tumor to which the 8H9 antibody will bind.
- For patients with tumors other than DSCRT, the tumor must have progressed or recurred despite prior standard therapy.
- At least 3 weeks must have passed since completion of prior chemotherapy or radiation therapy and 4 weeks since biological therapy or immunotherapy and entry into the study.
- Patients must be older than age 1.
For more information about this study and to inquire about eligibility, please contact Dr. Shakeel Modak at 212-639-7623.